Athanasios Mavratzas
Heidelberg University
13 Papers
6 Citations
Athanasios Mavratzas is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 10 publications.
Chat about Author
Papers
Completion rate and impact on physician-patient relationship of video consultations in medical oncology: a randomised controlled open-label trial.
Thomas Walle,Erkin Erdal,Leon Mühlsteffen,Hans Martin Singh,Editha Gnutzmann,Barbara Grün,Helene Hofmann,Alexandra Ivanova,Bruno Köhler,Felix Korell,Athanasios Mavratzas,Andreas Mock,Constantin Pixberg,David Schult,Helen Starke,Niels Steinebrunner,Lena Woydack,Andreas Schneeweiss,Mareike Dietrich,Dirk Jäger,Johannes Krisam,Jakob Nikolas Kather,Eva C. Winkler +22 more
- 01 Nov 2020
TL;DR: Follow-up visits with the tested mobile phone video call application were feasible but software compatibility should be critically evaluated.
28
First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.
Ugur Sahin,Dirk Jaeger,Frederik Marmé,Athanasios Mavratzas,Jürgen Krauss,Jacques De Greve,Ignace Vergote,Ö. Türeci +7 more
TL;DR: IMAB027 is the first-in-class monoclonal chemotherapy drug for ovarian cancer which has the potential to transform the way patients are diagnosed and treated.
17
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?
TL;DR: In this article, the authors present a review of current evidence from pro-and retrospective studies and give an outlook on future developments with respect to novel therapeutic agents, including oral SERD and AKT inhibitors, which have the potential to change the therapeutic landscape in the future.
13
High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cells.
TL;DR: A method for high-level production and purification of a fully functional immunoRNase fusion protein from supernatants of stably transfected mammalian cells is described.
5
Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis
Stephanie Rosenkaimer,T. Sieburg,L Winter,Athanasios Mavratzas,Wolf-Karsten Hofmann,Ralf-Dieter Hofheinz,Ibrahim Akin,Daniel Duerschmied,Anna Hohneck +8 more
TL;DR: Treatment-related cardiovascular events are relatively common in about one third of patients with breast cancer, and women with a cardiovascular risk profile or an advanced stage disease had a higher risk for adverse events.
4